The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1754
In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction
PDF:   US English
Disclosures
Principal Faculty
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy and safety of sildenafil oral film (Vybrique) for treatment of erectile dysfunction.
 Select a term to see related articles  alprostadil   avanafil   Cialis   erectile dysfunction   Eroxon   sildenafil   Stendra   tadalafil   vardenafil   Viagra   Vybrique 
Med Lett Drugs Ther. 2026 May 11; 68(1754):78-9   doi:10.58347/tml.2026.1754e

The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets (Viagra, and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.

Pronunciation Key
Vybrique: vye breek’

STANDARD TREATMENT — Oral PDE5 inhibitors (see Table 1) are generally used for initial treatment of ED. A nonmedicated, alcohol-based topical gel (Eroxon) is authorized by the FDA for sale over the counter for treatment of erectile dysfunction in men ≥22 years old.1 Other treatment options include vacuum-assisted erection devices, intraurethral or intracavernosal alprostadil, and penile implants.2 Low-intensity extracorporeal shockwave therapy (not approved by the FDA) has gained popularity for treatment of ED, but quality evidence demonstrating its long-term effectiveness is lacking.3

MECHANISM OF ACTION — Sildenafil is a selective inhibitor of PDE5. Inhibition of PDE5 increases cyclic guanosine monophosphate (cGMP) levels in the corpus cavernosum, which leads to smooth muscle relaxation and inflow of blood.

Table 1. Oral PDE5 Inhibitors for Erectile Dysfunction
Drug
Formulations
Usual Dosage1
Cost2
Avanafil – generic
Stendra (Petros)
50, 100, 200 mg tabs
100 mg PRN ~15 min before sexual activity
(max 200 mg once/day)
$56.30
70.003
Sildenafil – generic
Viagra (Viatris)
Vybrique (IBSA)
25, 50, 100 mg tabs
25, 50, 75, 100 mg films
50 mg PRN ~1 hr before sexual activity4
(max 100 mg once/day)
0.30
87.40
10.00
Tadalafil – generic
Cialis (Lilly)
2.5, 5, 10, 20 mg tabs
10 mg PRN ≥30 min before sexual activity
(max 20 mg once/day) or 2.5-5 mg once/day5
0.30
56.30
Vardenafil – generic
2.5, 5, 10, 20 mg tabs;
10 mg ODT
10 mg PRN ~1 hr before sexual activity
(max 20 mg once/day)
4.70
29.00
ODT = orally disintegrating tablet
1. Dosage adjustments may be needed for hepatic or renal impairment or for drug interactions.
2. Approximate WAC for one PRN dose. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published
catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. April 5, 2026. Reprinted with permission by First
Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/policies/drug-pricing-policy.
3. Cost without insurance at hims.com.
4. Can be taken 30 minutes to 4 hours before sexual activity.
5. Taken at the same time each day without regard to sexual activity.

CLINICAL STUDIES — FDA approval of sildenafil oral film was based on earlier trials with sildenafil tablets and one placebo-controlled trial (summarized in the package insert) in 475 men with ED in which the rate of successful sexual intercourse attempts over 12 weeks was significantly higher in men who used sildenafil oral film.

ADVERSE EFFECTS — Adverse effects of sildenafil include headache, flushing, dyspepsia, sudden vision loss, nasal congestion, and back pain. Prolonged erection/priapism can occur. Nonarteritic anterior ischemic optic neuropathy (NAION), retinal detachment, sudden hearing loss, decreased blood pressure, cardiovascular or cerebrovascular events, and syncope have been reported with PDE5 inhibitors.

DRUG INTERACTIONS — Like the other PDE5 inhibitors, sildenafil is metabolized by CYP3A4. Inhibitors of CYP3A4 can markedly increase sildenafil serum concentrations.4 All PDE5 inhibitors can increase the hypotensive effects of organic nitrates such as nitroglycerin and guanylate cyclase stimulators such as riociguat; they are contraindicated for use in patients taking these drugs. They may also potentiate the antihypertensive effects of alpha blockers, other antihypertensive drugs, and alcohol.

DOSAGE AND ADMINISTRATION — Vybrique is available for home delivery. It is supplied in cartons containing 4 or 8 individually packaged oral films, each containing 25, 50, 75, or 100 mg of sildenafil. The film should be placed on the tongue and swallowed with saliva once it has dissolved; it should not be cut or chewed. The recommended dosage is 50 mg taken as needed about one hour (30 minutes to 4 hours) before sexual activity; the dose can be increased to a maximum of 100 mg. Only one dose should be taken each day. The recommended starting dosage is 25 mg in patients who are taking a strong CYP3A4 inhibitor or alpha blocker, have hepatic or severe renal impairment, or are >65 years old.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article